CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Torasemide

托拉塞米 杂质对照品Torasemide Impurities

EP36 个杂质条目36 impurity entries

本页汇总 托拉塞米 的 36 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 36 impurity reference standards of Torasemide with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 托拉塞米(Torasemide)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesChemometrically assisted development and validation of LC-UV and LC-MS methods for simultaneous determination of torasemide and its impurities
    Journal of chromatographic science · 2012 · Jovic Z et al.  ·  PMID 22407343  ·  DOI
  2. 杂质研究Impurity studiesCharacterization of forced degradation products of torasemide through MS tools and explanation of unusual losses observed during mass fragmentation of drug and degradation products through density functional theory
    Journal of pharmaceutical and biomedical analysis · 2017 · Kurmi M et al.  ·  PMID 28666167  ·  DOI
  3. 杂质研究Impurity studiesDevelopment and Performance of a Highly Sensitive Model Formulation Based on Torasemide to Enhance Hot-Melt Extrusion Process Understanding and Process Development
    AAPS PharmSciTech · 2018 · Evans RC et al.  ·  PMID 29488197  ·  DOI
  4. 分析方法Analytical MethodsOptimization and Validation of a Sensitive Method for HPLC-PDA Simultaneous Determination of Torasemide and Spironolactone in Human Plasma using Central Composite Design
    Acta chimica Slovenica · 2015 · Subramanian V et al.  ·  PMID 26454598  ·  DOI
  5. 分析方法Analytical MethodsDetermination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry
    Journal of pharmaceutical analysis · 2016 · Zhang L et al.  ·  PMID 29403968  ·  DOI

托拉塞米 —— 原料药与杂质对照品Torasemide — drug substance & impurities

共 36 个条目(含原料药本体)36 items incl. the drug substance
Torasemide Impurity 9 (Torasemide EP Impurity A) structure
EPA
托拉塞米杂质9 (托拉塞米EP杂质A)Torasemide Impurity 9 (Torasemide EP Impurity A)
Torasemide Impurity 9 (Torasemide EP Impurity A)
CAS No.72810-61-8
Chemical FormulaC13H11N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 2 (Torasemide EP Impurity B) structure
EPB
托拉塞米杂质2 (托拉塞米EP杂质B)Torasemide Impurity 2 (Torasemide EP Impurity B)
Torasemide Impurity 2 (Torasemide EP Impurity B)
CAS No.72811-73-5
Chemical FormulaC12H13N3O2S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 3 (Torasemide EP Impurity C) structure
EPC
托拉塞米杂质3 (托拉塞米EP杂质C)Torasemide Impurity 3 (Torasemide EP Impurity C)
Torasemide Impurity 3 (Torasemide EP Impurity C)
CAS No.58155-35-4
Chemical FormulaC15H18N4O3S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 4 (Torasemide EP Impurity D) structure
EPD
托拉塞米杂质4 (托拉塞米EP杂质D)Torasemide Impurity 4 (Torasemide EP Impurity D)
Torasemide Impurity 4 (Torasemide EP Impurity D)
CAS No.160972-33-8
Chemical FormulaC17H22N4O3S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 5 (Torasemide EP Impurity E) structure
EPE
托拉塞米杂质5 (托拉塞米EP杂质E)Torasemide Impurity 5 (Torasemide EP Impurity E)
Torasemide Impurity 5 (Torasemide EP Impurity E)
CAS No.72810-57-2
Chemical FormulaC15H17N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 1 structure
1
托拉塞米杂质1Torasemide Impurity 1
Torasemide Impurity 1
CAS No.947327-54-0
Chemical FormulaC13H13N3O2S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 11 structure
11
托拉塞米杂质11Torasemide Impurity 11
Torasemide Impurity 11
CAS No.106944-63-2
Chemical FormulaC16H20N4O3S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 12 structure
12
托拉塞米杂质12Torasemide Impurity 12
Torasemide Impurity 12
CAS No.106944-62-1
Chemical FormulaC16H20N4O3S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 14 structure
14
托拉塞米杂质14Torasemide Impurity 14
Torasemide Impurity 14
CAS No.164595-81-7
Chemical FormulaC12H13N3O2S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 15 structure
15
托拉塞米杂质15Torasemide Impurity 15
Torasemide Impurity 15
CAS No.164595-80-6
Chemical FormulaC12H13N3O2S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 18 structure
18
托拉塞米杂质18Torasemide Impurity 18
Torasemide Impurity 18
CAS No.33263-44-4
Chemical FormulaC5H3Cl2NO2S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 19 structure
19
托拉塞米杂质19Torasemide Impurity 19
Torasemide Impurity 19
CAS No.51498-38-5
Chemical FormulaC5H4ClNO3S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 20 structure
20
托拉塞米杂质20Torasemide Impurity 20
Torasemide Impurity 20
CAS No.57724-91-1
Chemical FormulaC5H5ClN2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 24 structure
24
托拉塞米杂质24Torasemide Impurity 24
Torasemide Impurity 24
CAS No.51498-37-4
Chemical FormulaC5H5NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 27 structure
27
托拉塞米杂质27Torasemide Impurity 27
Torasemide Impurity 27
CAS No.58154-83-9
Chemical FormulaC16H20N4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 28 structure
28
托拉塞米杂质28Torasemide Impurity 28
Torasemide Impurity 28
CAS No.2594-20-9
Chemical FormulaC6H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 29 structure
29
托拉塞米杂质29Torasemide Impurity 29
Torasemide Impurity 29
CAS No.33263-43-3
Chemical FormulaC5H5ClN2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 30 structure
30
托拉塞米杂质30Torasemide Impurity 30
Torasemide Impurity 30
CAS No.5602-90-4
Chemical FormulaC5H11NO2
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 31 structure
31
托拉塞米杂质31Torasemide Impurity 31
Torasemide Impurity 31
CAS No.56176-07-9
Chemical FormulaC13H10ClN3O2S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 32 structure
32
托拉塞米杂质32Torasemide Impurity 32
Torasemide Impurity 32
CAS No.113844-99-8
Chemical FormulaC16H18N4O5S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 33 structure
33
托拉塞米杂质33Torasemide Impurity 33
Torasemide Impurity 33
CAS No.99300-67-1
Chemical FormulaC16H20N4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 34 structure
34
托拉塞米杂质34Torasemide Impurity 34
Torasemide Impurity 34
CAS No.99300-68-2
Chemical FormulaC16H20N4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 38 structure
38
托拉塞米杂质38Torasemide Impurity 38
Torasemide Impurity 38
CAS No.2740482-59-9
Chemical FormulaC10H7Cl2N3O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 43 structure
43
托拉塞米杂质43Torasemide Impurity 43
Torasemide Impurity 43
CAS No.740746-58-1
Chemical FormulaC12H13N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 48 structure
48
托拉塞米杂质48Torasemide Impurity 48
Torasemide Impurity 48
CAS No.2740482-60-2
Chemical FormulaC24H23N5O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 49 structure
49
托拉塞米杂质49Torasemide Impurity 49
Torasemide Impurity 49
CAS No.16066-84-5
Chemical FormulaC6H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 51(Pyrimethanil) structure
51
托拉塞米杂质51(嘧霉胺)Torasemide Impurity 51(Pyrimethanil)
Torasemide Impurity 51(Pyrimethanil)
CAS No.53112-28-0
Chemical FormulaC12H13N3
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 52 structure
52
托拉塞米杂质52Torasemide Impurity 52
Torasemide Impurity 52
CAS No.81261-84-9
Chemical FormulaC12H13N3O
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 53 structure
53
托拉塞米杂质53Torasemide Impurity 53
Torasemide Impurity 53
CAS No.2971-90-6
Chemical FormulaC7H7Cl2NO
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 62 structure
62
托拉塞米杂质62Torasemide Impurity 62
Torasemide Impurity 62
CAS No.137783-27-8
Chemical FormulaC14H22N4O2S2
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 63 structure
63
托拉塞米杂质63Torasemide Impurity 63
Torasemide Impurity 63
CAS No.72842-96-7
Chemical FormulaC14H22N4O3S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 64 structure
64
托拉塞米杂质64Torasemide Impurity 64
Torasemide Impurity 64
CAS No.204499-30-9
Chemical FormulaC11H11N3O2S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 65 structure
65
托拉塞米杂质65Torasemide Impurity 65
Torasemide Impurity 65
CAS No.72811-66-6
Chemical FormulaC16H17ClN4O3S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 67 structure
67
托拉塞米杂质67Torasemide Impurity 67
Torasemide Impurity 67
CAS No.58155-33-2
Chemical FormulaC15H18N4O3S
Purity>95%询价On request
10mg25mg50mg100mg
Torasemide Impurity 51-d5 structure
51-D5
托拉塞米杂质51-d5Torasemide Impurity 51-d5
Torasemide Impurity 51-d5
CAS No.2118244-83-8
Chemical FormulaC12H8D5N3
Purity>95%询价On request
Torasemide Impurity 52-d4 structure
52-D4
托拉塞米杂质52-d4Torasemide Impurity 52-d4
Torasemide Impurity 52-d4
CAS No.1794897-91-8
Chemical FormulaC12H9D4N3O
Purity>95%询价On request

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

托拉塞米 —— 研究文献与合成路线Torasemide — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 托拉塞米 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Torasemide. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Characterization of forced degradation products of torasemide through MS tools and explanation of unusual losses observed during mass fragmentation of drug and degradation products through density functional theory
    Kurmi M, Patel N, Jhajra S, et al. · Journal of pharmaceutical and biomedical analysis · 2017 · 被引 5cited 5
  2. Chemometrically assisted development and validation of LC-UV and LC-MS methods for simultaneous determination of torasemide and its impurities
    Jovic Z, Zivanovic L, Radisic M, et al. · Journal of chromatographic science · 2012

合成与制备工艺专利Synthesis & process patents

  1. Process for preparing Torasemide intermediate and its analogue
    CAO YUPING JIANG · 公开号 CN1844100CN1844100 · 2006
  2. PREPARATION OF TORASEMIDE
    YEH WEN-LUNG, KHUMTAVEEPORN KANJAI, MCKENZIE DAVID JOHN · 公开号 WO2004089904WO2004089904 · 2004
  3. PREPARATION OF TORASEMIDE
    MCKENZIE DAVID JOHN, KHUMTAVEEPORN KANJAI, YEH WEN-LUNG · 公开号 CA2424644CA2424644 · 2004
  4. Torasemide freeze-drying preparation and prepn. method
    CAO YUPING JIANG · 公开号 CN1833642CN1833642 · 2006
  5. Torasemide-containing pharmaceutical preparations
    MAEGERLEIN MARKUS, HANTKE THOMAS, BREITENBACH JORG, ROSENBERG JORG · 公开号 US2003153608US2003153608 · 2003

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

托拉塞米 杂质谱研究要点Torasemide — impurity profiling notes

下面这些是拿到 托拉塞米 的 36 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 36 impurity entries for Torasemide, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances